Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center

被引:12
作者
Kodad, Shruthi Ganeshappa [1 ]
Sutherland, Heather [1 ]
Limvorapitak, Wasithep [1 ]
Abou Mourad, Yasser [1 ]
Barnett, Michael J. [1 ]
Forrest, Donna [1 ]
Gerrie, Alina [1 ]
Hogge, Donna E. [1 ]
Nantel, Stephen H. [1 ]
Narayanan, Sujaatha [1 ]
Nevill, Thomas [1 ]
Power, Maryse [1 ]
Sanford, David [1 ]
Toze, Cynthia [1 ]
White, Jennifer [1 ]
Broady, Raewyn [1 ]
Song, Kevin [1 ]
机构
[1] Vancouver Gen Hosp, Leukemia Bone Marrow Transplant Program British C, BC Canc, Vancouver, BC, Canada
关键词
Autotransplant; Feasibility; MM; Outpatient transplant; Resource utilization; COST; TRENDS;
D O I
10.1016/j.clml.2019.09.619
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-dose chemotherapy and autologous stem cell transplant is a standard consolidative treatment option for patients with multiple myeloma. Outpatient care models are necessary in today's era owing to increasing patient volumes and limited resources. This study emphasizes the feasibility of autologous stem cell transplant in an outpatient model of care and outlines the resources necessary to run such a unit. Background: Autologous stem cell transplant (ASCT) is the preferred consolidation strategy to treat eligible patients with multiple myeloma (MM) and related plasma cell dyscrasias. Given the increasing volume of patients and longer wait time, outpatient ASCT for MM is the standard of care at the Vancouver General Hospital. Patients and Methods: Patients with MM, POEMS syndrome, and amyloidosis undergoing ASCT were included in this analysis. We analyzed patient characteristics, the number of patients requiring admission, duration of admission, 30-day and 100-day mortality, and overall survival. Results: Between January 2007 and June 2016, 724 patients underwent 752 ASCTs. Of these, 702 were first ASCTs, 44 were second, and 6 were third. The median age was 60 years (interquartile range [IQR], 54-65 years). Reasons for ASCTs were MM (96.9%) amyloidosis (2.4%), and POEMS syndrome (0.7%). There were 431 (59.5%) males in this group. The median time from diagnosis to transplant was 5 months. Conditioning was melphalan 200 mg/m(2) for 89.6% of the patients. Admission to the inpatient ward was required by 245 (32.6%) patients within the first 30 days. The median time to admission was 9 days post-transplant (IQR, 5-13 days). The median duration of admission was 6 days (IQR, 3-9 days). The day 100 all-cause mortality rate was 0.9%, and transplant-related mortality was 0.4%. Conclusion: Outpatient ASCT is a safe and feasible treatment strategy with low transplant-related mortality. Overall resource utilization is significantly lower than inpatient ASCT: however, this requires a multidisciplinary approach with close follow-up. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:784 / 790
页数:7
相关论文
共 18 条
  • [1] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
    Attal, Michel
    Lauwers-Cances, Valerie
    Hulin, Cyrille
    Leleu, Xavier
    Caillot, Denis
    Escoffre, Martine
    Arnulf, Bertrand
    Macro, Margaret
    Belhadj, Karim
    Garderet, Laurent
    Roussel, Murielle
    Payen, Catherine
    Mathiot, Claire
    Fermand, Jean P.
    Meuleman, Nathalie
    Rollet, Sandrine
    Maglio, Michelle E.
    Zeytoonjian, Andrea A.
    Weller, Edie A.
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    Facon, Thierry
    Avet-Loiseau, Herve
    Harousseau, Jean-Luc
    Moreau, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) : 1311 - 1320
  • [2] Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment
    Clemmons, Amber B.
    Anderegg, Samm
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (05) : 384 - 388
  • [3] Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma
    Costa, Luciano J.
    Zhang, Mei-Jie
    Zhong, Xiaobo
    Dispenzieri, Angela
    Lonial, Sagar
    Krishnan, Amrita
    Freytes, Cesar
    Vesole, David
    Gale, Robert Peter
    Anderson, Kenneth
    Wirk, Baldeep
    Savani, Bipin N.
    Waller, Edmund K.
    Schouten, Harry
    Lazarus, Hillard
    Meehan, Kenneth
    Sharma, Manish
    Kamble, Rammurti
    Vij, Ravi
    Kumar, Shaji
    Nishihori, Taiga
    Kindwall-Keller, Tamila
    Saber, Wael
    Hari, Parameswaran N.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (11) : 1615 - 1624
  • [4] Current Use and Trends in Hematopoietic Cell Transplantation in the United States
    D'Souza, Anita
    Lee, Stephanie
    Zhu, Xiaochun
    Pasquini, Marcelo
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (09) : 1417 - 1421
  • [5] From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
    Gay, Francesca
    Engelhardt, Monika
    Terpos, Evangelos
    Waesch, Ralph
    Giaccone, Luisa
    Auner, Holger W.
    Caers, Jo
    Gramatzki, Martin
    van de Donk, Niels
    Oliva, Stefania
    Zamagni, Elena
    Garderet, Laurent
    Straka, Christian
    Hajek, Roman
    Ludwig, Heinz
    Einsele, Herman
    Dimopoulos, Meletios
    Boccadoro, Mario
    Kroeger, Nicolaus
    Cavo, Michele
    Goldschmidt, Hartmut
    Bruno, Benedetto
    Sonneveld, Pieter
    [J]. HAEMATOLOGICA, 2018, 103 (02) : 197 - 211
  • [6] Autologous stem cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative
    Gertz, Morfe A.
    Ansell, Stephen M.
    Dingli, David
    Dispenzieri, Angela
    Buadi, Francis K.
    Elliott, Michelle A.
    Gastineau, Dennis A.
    Hayman, Suzanne R.
    Hogan, William J.
    Inwards, David J.
    Johnston, Patrick B.
    Kumar, Shaji
    Lacy, Martha Q.
    Leung, Nelson
    Micallef, Ivana N. M.
    Porrata, Luis F.
    Schafer, Barbara A.
    Wolf, Robert C.
    Litzow, Mark R.
    [J]. MAYO CLINIC PROCEEDINGS, 2008, 83 (10) : 1131 - 1135
  • [7] Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Dingli, David
    Gonsalves, Wilson I.
    Kumar, Shaji
    Kapoor, Prashant
    Kourelis, Taxiarchis
    Hogan, William J.
    [J]. MAYO CLINIC PROCEEDINGS, 2018, 93 (01) : 56 - 58
  • [8] Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
    Gonsalves, Wilson I.
    Buadi, Francis K.
    Ailawadhi, Sikander
    Bergsagel, P. Leif
    Khan, Asher A. Chanan
    Dingli, David
    Dispenzieri, Angela
    Fonseca, Rafael
    Hayman, Susan R.
    Kapoor, Prashant
    Kourelis, Taxiarchis V.
    Lacy, Martha Q.
    Larsen, Jeremy T.
    Muchtar, Eli
    Reeder, Craig B.
    Sher, Taimur
    Stewart, A. Keith
    Warsame, Rahma
    Go, Ronald S.
    Kyle, Robert A.
    Leung, Nelson
    Lin, Yi
    Lust, John A.
    Russell, Stephen J.
    Zeldenrust, Stephen R.
    Fonder, Amie L.
    Hwa, Yi L.
    Hobbs, Miriam A.
    Mayo, Angela A.
    Hogan, William J.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    Gertz, Morie A.
    Roy, Vivek
    [J]. BONE MARROW TRANSPLANTATION, 2019, 54 (03) : 353 - 367
  • [9] Safety and Cost-Effectiveness of Outpatient Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
    Holbro, Andreas
    Ahmad, Imran
    Cohen, Sandra
    Roy, Jean
    Lachance, Silvy
    Chagnon, Miguel
    LeBlanc, Richard
    Bernard, Lea
    Busque, Lambert
    Roy, Denis Claude
    Sauvageau, Guy
    Kiss, Thomas L.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (04) : 547 - 551
  • [10] Role of stem cell transplant and maintenance therapy in plasma cell disorders
    McCarthy, Philip L.
    Holstein, Sarah A.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 504 - 511